The New Economy and its Winners Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The New Economy and its Winners

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Bill Harmond

1/9/2017 12:55:39 PM

of 57684

09-Jan-17
08:05	EDIT Editas Medicine outlines 2017 goals ahead of JP Morgan Conference at January 11 (17.51 )
	Driving Editas Medicine's unparalleled platform for genome editing medicines. As the only company with access to the CRISPR genome editing systems Cas9, advanced forms of Cas9, and the novel Cpf1 genome editing system, Editas Medicine has the potential to treat the broadest range of diseases through efficient editing of nearly any genetic target. Advancing a pipeline strategy to enable successful product development in the years ahead. For Editas Medicine's LCA10 program, this includes achieving the first in vivo proof-of-editing in the retina of non-human primates, as well as the Company's goal to submit an IND for the LCA10 program by the end of 2017. In addition, Ms. Bosley will discuss recent progress in achieving consistent, durable editing in hematopoietic stem cells and high efficiency editing of CAR-T cells. Building the business for the long term by assembling the capabilities to fully develop and commercialize important medicines. This includes aggressively developing valuable partnerships, robust financial resources, an unmatched patent position, and an outstanding team and culture to drive Editas Medicine's bold vision for years to come. Ms. Bosley will outline the Company's 2017 goals, including driving the following critical initiatives: Submitting an IND for the LCA10 program by year-end 2017 Initiating an LCA10 clinical natural history study in mid-2017 Achieving preclinical proof-of-concept for additional programs Establishing additional alliances aligned with the Company's business development strategy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next